XFOR
X4 Pharmaceuticals Inc
Halal Rating :
Last Price
$0.51
Last updated:
Market Cap
-
7D Change
-9.69%
1 Year Change
-33.92%
Company Overview
Industries
Exchange
Next Earnings Date
X4 Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of rare diseases. Their lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4 being developed for the treatment of WHIM syndrome, a rare primary immunodeficiency disease, and other chronic neutropenic disorders.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $560000.0 | $37.47m | - | $2.41m | 0.00% | 6.44% |
| June 30, 2024 | $563000.0 | $-68364000.0 | - | $2.18m | 0.00% | 3.18% |
Company Impact
Help us evaluate X4 Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.